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Effect of para-aminohippurate on renal transport of oxalate. In-
fusion of para-aminohippurate (PAH) at rates below the maxi-
mum rate of transport (Tm) of PAH in the rat resulted in a signifi-
cant decrease in the fractional excretion of oxalate (FE0) from
128.1% to 113.9% (P < 0.01). Fractional delivery of oxalate
(FD0) to the early proximal tubule, however, was unchanged
from control values, whereas FD0,, to the late proximal tubule
was significantly decreased from 126.4% to 107.4% (P < 0.01).
Infusion of PAH at rates above Tm of PAH resulted in a decrease
in FD0 to the early proximal tubule to 105.3% and to the late
proximal tubule to 105.5%, and in FE0 to 100.5%. These
changes were not the result of alterations in urinary sodium or
bicarbonate excretion. Microinjection studies indicated that
PAH did not affect the tubular absorption of oxalate. These stud-
ies suggest that PAH inhibits the tubular secretion of oxalate and
that there may be more than one secretory system for oxalate
with differing affinities for oxal ate and PAH in the early and late
proximal tubules.
Effet du para-aminohippurate sur le transport renal de
l'oxalate. La perfusion de para-aminohippurate (PAH) a des dé-
bits inférieurs au Tm PAH chez le rat a pour consequence une
diminution significative de 1' excretion fractionnelle de l'oxalate
(FE0) de 128,1% a 113,9% (P < 0,01). La fraction délivrée,
FD0, au tube contourné proximal precoce, n'est cependant pas
différente des valeurs contrôles alors que FD0 au tube proximal
tardif diminue significativement de 126,4% a 107,4% (P < 0,01).
La perfusion de PAH a des debits superieurs au Tm PAH a pour
consequence une diminution de FD0 au tube proximal précoce
a 105,3%, a 105,5% au tube proximal tardif, et a 100,5% pour
FE0. Ces modifications ne sont pas les consequences de modifi-
cations de l'excrétion urinaire de bicarbonate ou de sodium. Des
microinjections montrent que le PAH ne modifie pas la reabsorp-
tion de l'oxalate. Ces etudes suggèrent que le PAl-I inhibe Ia
secretion tubulaire de l'oxalate et qu'ilpourrait y avoir plud d'un
systéme de secretion pour l'oxalate avec des affinités différentes
pour l'oxalate et le PAH dans le tube proximal précoce et tardif.
In man, dog, and sheep, oxalate undergoes secre-
tion by the renal tubular cells such that the clear-
ance of oxalate in the final urine exceeds that of the
glomerular filtration rate [1—41. Prior studies from
this laboratory have advanced evidence that there is
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net tubular secretion of oxalate by the renal tubular
cells of the rat kidney [5]. Those studies also have
indicated that the renal handling of oxalate differs
from that of PAH in two ways. First, the nephron
sites subserving the tubular secretion of these two
organic acids differs. Second, the systemic adminis-
tration of probenecid alters the renal handling of
PAH but is without effect on oxalate transport [5].
To further understand the mechanism or mecha-
nisms by which the rat kidney transports oxalate,
we used free-flow micropuncture and clearance
studies to examine the effects of PAH on oxalate
excretion.
Methods
All studies were performed in male Sprague-
Dawley rats anesthetized with pentobarbital (Nem-
butal, 50 to 60 mg/kg of body wt), and the rats were
prepared for micropuncture as previously described
[61. A volume of isotonic saline equal to 1% of body
weight was infused i.v. during the surgical prepara-
tion of the animal.
Free-flow micropuncture studies. One milliliter of
a solution containing [14C]-oxalate (75 CiIml) and
[3H-methoxy]-inulin (75 ttCiIml) was infused as a
prime, followed by a sustaining infusion of the same
solution at a rate of 1.2 ml/hr. After 60 to 90 mm of
equilibration, free-flow micropuncture samples were
obtained from early and/or late proximal tubular
sites. Initial localization of micropuncture sites
was done either by the lissamine green transit time
method or by the injection of small oil droplets and
noting their movement along the nephron. Puncture
sites were confirmed by microdissection of latex
casts of tubules. Appropriate blood and urine col-
lections were obtained throughout the study for cal-
culation of clearance values. At the conclusion of
the experiments, a large blood sample was obtained
for ultrafiltration studies and determination of
plasma PAH concentrations.
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Preliminary studies indicated that infusion of low
doses of PAH had a small and variable effect on
oxalate excretion. Accordingly, in 15 animals, mi-
cropuncture samples and urine and blood samples
were obtained during control periods, after which a
bolus of 9 mg of PAH per 100 g of body wt was
infused followed by a sustaining infusion of PAH, 9
mg/100 g of body wt per hour, dissolved in distilled
water. Urine volume losses were replaced with iso-
tonic saline infused at a rate equal to the rate of
urine flow. After 60 mm of equilibration, repeat mi-
cropuncture samples were obtained from pre-
viously unpunctured nephrons. Blood and urine
samples were also obtained. In eight animals, a
higher dose of PAH (bolus of 50 mg/100 g of body
wt, followed by a sustaining infusion of 50 mg/l00 g
of body wt per hour of PAH dissolved in distilled
water) was given after completion of micropuncture
surgery. No control clearance periods were obtained
in these animals. Urinary losses were replaced with
isotonic saline at a rate equal to the urine flow rate.
After 90 mm of equilibration, tubular fluid, blood,
and urine samples were obtained.
Since the doses of PAH infused, especially the
higher dose, markedly increased the urinary ex-
cretin of sodium, we examined the effect of expan-
sion of the extracellular fluid volume with isotonic
saline (seven animals) or isotonic sodium bicarbo-
nate (five animals). After sample collection in the
control periods, we infused a volume of either solu-
tion equal to 10% of body wt over 60 mm, after
which we adjusted the infusion rate to match the
urine flow rate. In these studies, repeat micro-
puncture samples were obtained only from late
proximal tubule sites. Since control values for both
these volume expansion studies were similar, we
pooled the results for the purposes of presentation
of the data.
Clearances are expressed as microliters per min-
ute per gram of kidney weight and are calculated
from standard formulae. Fractional excretion, ex-
pressed as percentage, was calculated from the
clearance rates of oxalate and inulin. The fractional
delivery rate to the point of micropuncture was
calculated from the expression
TFP0fractional delivery (%) = x 100Irir
where TF and P are the disintegrations per minute
in tubular fluid (TF) and plasma (P) of oxalate (Ox)
and inulin (In).
Microinjection studies. To determine if PAH had
any effect on oxalate absorption, we prepared the
animals for study as above, except that we infused
no isotopes systemically and we catheterized the
left ureter with PE-50 tubing. A solution of 5% man-
nitol in normal saline was infused at 12 mi/hr to en-
sure high urine flow rates. The intratubular micro-
injection solutions contained [14C]-oxalate (50 Ci/
ml) and [3H]-inulin (50 Ci/ml). Microinjections
were made into early proximal tubules during con-
trol conditions, following which the animals re-
ceived a bolus of PAH of 50 mg/100 g body wt and
then a sustaining infusion of 50 mg/l00 g of body wt
per hour. After a 1-hour equilibration period, re-
peat microinjections were made into previously Un-
punctured early proximal tubules. A microinjection
solution of 10 to 12 nl was microinjected over a
120-sec interval. After each microinjection, urine
was collected sequentially from both left and right
kidneys in 60-sec aliquots. The procedures for mi-
croinjection, localization of micropuncture sites,
and calculations of the fractional recovery rates in
the urine have previously been described in detail
from this laboratory [6].
Ultrafilterability of [14C]-oxalate was determined
in an ultracentrifuge using Amicon ultrafiltration
cones (Amicon Corp., Lexington, Mass.) Hemato-
crits were measured in microhematocrit tubes.
Urine sodium concentrations were determined by
flame photometry. Plasma PAH concentrations
were measured using the method of Smith et al [71.
Radioactivity of blood, tubular fluid, and urine was
determined in Biofluor (New England Nuclear,
Boston, Mass.) in a Packard Tri-carb liquid scintil-
lation counter (Packard Instruments Co., Inc.,
Downers Grove, Ill.) Counts per minute were con-
verted to disintegrations per minute after correction
for quenching, crossover counts, and efficiency of
counting of each isotope. For each animal, calcu-
lations of micropuncture and urine data are aver-
aged and the results expressed as the mean of means
SEM. Statistical significance was determined by
Student's t tests for paired and unpaired data where
appropriate.
Results
The ratio of [14C]-oxalate/[3H-,net/ioxy]-inulin in
ultrafiltrates of plasma obtained at the conclusion of
the experiments, compared to the ['4C]-oxalate/[3H-
tnethoxvJ-inulin ratio of the plasma, was 1.01
0.03, a value not significantly different from 1. In
control periods (Table 1), the fractional delivery
rates of oxalate to the early portion of the proximal
tubule averaged 123.2 3.0%. The fractional deliv-
ery rate to the late proximal tubule (126.2 4.2%)
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kidney WI kidney WI % TF/P1 x 100 TF/P1 x 100 kidney WI vol. % mgI 100ml
Control 1032 59 1312 85 128.1 2.5 1.52 0.10 123.2 3.0 2.68 0.16 126.2 4.2 0.08 0.01 51.4 0.8 —
PAH
(low dose) 1006 40 1146 46 113.9 2.6 1.33 0.07 121.0 3.0 2.27 0.20 107.4 5.6 1.53 0.37 51.0 0.7 4.7 0.8
pb NS <0.05 <0.01 NS NS <0.05 <0.01 <0.001 NS —
PAH
(high dose) 1334 77 1337 80 100.5 3.6 1.60 0.09 105.3 3.3 2.19 0.13 105.5 3.2 6.70 0.77 51.6 1.0 38.3 5.5
< 0.01 NS < 0.001 NS <0.001 < 0.02 < 0.001 < 0.001 NS —
a Values' represent mean of means SEM. Abbreviations are C0,, oxalate clearance; FE0, fractional excretion of oxalate; TFIP,
tubular fluid-to-plasma inulin (In) or oxalate (Ox); UNaV, urinary sodium excretion; and Hct, hematocrit.
b p values indicate statistical significance between values obtained in experimental animals as comparea to control animals.
and fractional excretion in the final urine (128.1
2.5) were not significantly different from values ob-
tained in the early proximal tubule. The infusion of
low doses of PAH resulted in plasma concentra-
tions of 4.7 0.8 mg/l00 ml (range, 2.0 to 13.5). In
these experiments, there was a significant decrease
in the fractional excretion of oxalate in the final
urine from 128.1 2.5 in controls to 113.9 2.6%
(P <0.01). The fractional delivery of oxalate to the
early proximal tubule, however, was not signifi-
cantly different from that of controls. In the late
proximal tubule, the fractional delivery of oxalate
averaged 107.4 5.6%, a value significantly lower
than that of the early proximal tubule (P <0.05) and
significantly lower than control values for this seg-
ment of the nephron (P <0.01), but not significantly
different from the fractional excretion of oxalate in
the final urine of the PAH periods. The infusion of
PAH did not affect the GFR, but it significantly in-
creased the urinary excretion of sodium from 0.08
0.01 to 1.53 0.37 Eq/min/g of kidney wt (P <
0.001). TF/P1 ratios in samples obtained from the
early proximal tubule were similar in both control
and experimental periods. End proximal TF/P1 val-
ues averaged 2.27 0.20 in the experimental pen-
ods, as compared to 2.68 0.16 in control periods
(P <0.05).
As compared to control values, the infusion of
higher concentrations of PAH (plasma concentra-
tions of 38.3 5.5 mg/100 ml) decreased the frac-
tional delivery of oxalate to the early proximal tu-
bule (105.3 3.3) and to the late proximal tubule
(105.5 3.2) and the fractional excretion in the final
urine (100.5 3.6). These values were not different
from one another. In these high-dose PAH infusion
studies, urine sodium excretion was markedly in-
creased to 6.70 0.77 /LEq/min/g of kidney wt, and
end-proximal TF/P1 decreased to 2.19 0.13, val-
ues significantly different from those obtained dur-
ing control periods.
The results of the microinjection studies in five
animals revealed a 79.3 1.8% urinary recovery of
microinjected oxalate during control conditions.
During infusion of PAH, urinary recovery of oxa-
late was 80.9 2.0 (P = NS). Inulin recoveries
were > 90% in all studies, and no significant inulin
counts appeared in the urine from the right kidney.
These results indicate that PAH did not enhance the
oxalate absorptive flux in the proximal convoluted
tubule.








kidney wt kidney wt % TFIP1 X 100 kidney WI vol. %
Control 999 50 1253 70 127.3 2.0 2.65 0.09 129.8 2.7 0.11 0.03 52.3 0.6
Sodium chloride 994 74 1184 83 121.6 2.1 1.35 0.05 123.6 2.0 6.91 1.99 41.9 1.2
ph NS NS NS <0.001 NS <0.001 <0.001
Sodium bicarbonate 1026 87 1224 108 119.0 3.9 1.46 0.12 117.4 5.1 16.92 0.68 42.2 0.4
ph NS NS NS <0.001 NS <0.001 <0.001
Values represent the mean of means SEM. See Table 1 for definition of abbreviations.
P values indicate statistical significance between values obtained in experimental animals as compared to control animals.
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Alterations in urine flow rate, sodium excretion,
or urine pH consequent to infusion of PAH conceiv-
ably could have affected oxalate excretion inde-
pendent of any effect of the PAH. To control for
these variables and to examine the effect of altera-
tions in the extracellular fluid volume and urine pH,
we volume-expanded the animals with either iso-
tonic saline or isotonic sodium bicarbonate. Control
values for these studies were similar to those of the
PAH control periods (Table 2). Volume expansion
with either saline or sodium bicarbonate resulted in
large increases in sodium excretion and similar de-
creases in end-proximal TF/P1 ratios. The fraction-
al delivery of oxalate to the end of the proximal tu-
bule and the fractional excretion in the final urine
were slightly but not significantly decreased in both
experimental protocols.
Discussion
In a prior study from this laboratory, we reported
that oxalate undergoes net secretion in the early
portion of the proximal tubule, and we also ad-
vanced evidence for bidirectional transport of equal
magnitude in the mid and late portions of the proxi-
mal tubule [5]. We were unable, however, to dem-
onstrate significant rates of transport in nephron
segments beyond the proximal convoluted tubule
accessible to micropuncture. The pattern of renal
oxalate transport was different from that of PAH in
that this latter organic compound was secreted in
the more distal part of the proximal tubule. Another
difference between the renal handling of oxalate and
PAH was that probenecid did not affect oxalate
transport but did inhibit that of PAH 115]. The cur-
rent study examines the effects of the systemic in-
fusion of PAH on renal oxalate transport and pro-
vides some further insights on this transport proc-
ess.
The infusion of PAH in amounts calculated to be
below the maximum rate of transport (Tm) for PAH
in the rat significantly decreased the fractional ex-
cretion of oxalate in the urine. In samples obtained
from the earliest accessible portion of the proximal
tubule, however, the fractional delivery rate of oxa-
late did not differ between control animals and ani-
mals receiving PAH. In samples obtained from the
late portion of the proximal tubule, on the other
hand, the fractional delivery of oxalate was signifi-
cantly lower and approximated that of the final
urine. Infusions of PAH in amounts above the Tm
for PAH inhibited oxalate transport throughout the
proximal tubule. Microinjection studies indicated
that PAH had no effect on oxalate absorption.
Thus, the effects of PAH or some metabolite of
PAH on the fractional delivery and excretion rates
of oxalate are due to an effect of PAH on the tubular
secretion of oxalate. These results are open to sev-
eral interpretations. There may be more than one
oxalate secretory system, each with a differing af-
finity for oxalate and PAH. In the mid to late por-
tions of the proximal tubule, the transport system
has some affinity for PAH, and when PAH is in-
fused there is a decrease in oxalate secretion. The
transport system located in the early proximal tu-
bule, however, has a higher affinity for oxalate and
a lower affinity for PAH, such that an effect of PAH
is not evident except at higher plasma concentra-
tions of PAH. Although we favor this inter-
pretation, it can be noted that the results of the
present studies can also be explained by the pres-
ence of a single oxalate secretory system with a
higher affinity for oxalate than for PAH. In this for-
mulation it is necessary to postulate that the num-
ber of secretory sites in the early proximal tubule
exceeds that of the late proximal tubule or, alterna-
tively, that there is a change in the PAH-to-oxalate
concentration ratio in the peritubular capillary
blood along the length of the proximal tubule. The
current studies do not permit a clear distinction be-
tween these possibilities.
It is necessary to reconcile the results of the pres-
ent studies with those of our prior investigations,
especially as to the effects of probenecid. As noted
earlier, probenecid had no effect on oxalate trans-
port, but it markedly inhibited that of PAH. It is
generally assumed that PAH secretion occurs by a
carrier-mediated transport mechanism that is sensi-
tive to probenecid inhibition; that is, probenecid
has a higher affinity for the carrier than does PAH
[7, 81. The possibility that some PAH secretion may
occur by other secretory mechanisms which are not
probenecid-sensitive has not been discussed in de-
tail in the published literature. We previously ob-
served that probenecid in a dose of 100 mg/kg of
body wt per hour markedly inhibited the urinary se-
cretion of PAH but did not totally abolish evidence
for secretion [51. Higher doses could not be exam-
ined, since the systemic infusions of higher doses of
probenecid are associated with a decrease in blood
pressure and in urine volume (unpublished observa-
tion). Thus, it is possible that some PAH transport
occurs via a probenecid-insensitive mechanism and
that one of these alternative mechanisms is in com-
mon with the transport mechanism for oxalate.
The systemic infusion of PAH has previously
been reported to have measurable effects on the
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tubular handling of sodium, and these findings are
confirmed in the present studies [10, 11]. During
high-dose PAH infusions, TF/P1 concentrations in
the proximal tubule were lower, urine volumes
higher, and urinary sodium excretions increased. It
might be considered if the changes in sodium han-
dling were responsible for the changes in oxalate
excretion. This does not appear to be the case,
since expansion of the extracellular fluid volume
with isotonic saline had little effect on oxalate ex-
cretion. Similar effects were noted with bicarbonate
infusions, suggesting that the pH of the urine did
not influence oxalate excretion. Oxalate transport
appears to be independent of sodium transport and
independent of the transport of the accompanying
anion. It seems unlikely, therefore, that the effects
of PAH on oxalate were the result of alterations in
sodium reabsorption, but rather, they suggest that
PAH was competitively inhibiting oxalate secre-
tion.
It has been previously suggested that oxalate is
freely filtered at the glomerulus [3]. In vitro ultrafil-
tration of plasma containing [14C1-oxalate indicated
the ratio of oxalate to inulin in the ultrafiltrate as
compared to the ratio of oxalate to inulin in the
plasma averaged 1.01. This finding may indicate
that oxalate is freely filterable. The dissociation of
the doubly negatively charged oxalate in solution,
however, is unknown. If it is completely dis-
sociated, the ultrafiltration ratio of 1 could be inter-
preted as a degree of plasma-binding equal to the
Donnan shift predicted for a doubly charged mole-
cule. Whatever the exact physiologic process, it ap-
pears valid to calculate clearance values of oxalate
from plasma levels.
In summary, then, the results of the present stud-
ies indicate that PAll inhibits the tubular secretion
of oxalate and results in a decreased excretion of
oxalate in the rat. This effect is due to the PAH it-
self and is not the result of changes in the renal ab-
sorption of sodium, chloride, or bicarbonate con-
sequent to the systemic infusion of PAH. The re-
sults raise the possibility of the presence of two or
more oxalate secretory mechanisms with differing
sensitivities to inhibition by PAH. By inference, the
present results may also indicate the presence of a
PAH secretory mechanism, linked to oxalate, but
not sensitive to probenecid.
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